PathAI will exclusively work with Roche Tissue Diagnostics (RTD) to develop artificial intelligence (AI) digital pathology algorithms for RTD's companion diagnostics business.

PathAI将专门与Roche Tissue Diagnostics（RTD）合作，为RTD的配套诊断业务开发人工智能（AI）数字病理算法。

The image analysis algorithms will be deployed on Roche's navify Digital Pathology platform, allowing seamless integration into pathology laboratories worldwide.

图像分析算法将部署在罗氏的navify数字病理学平台上，从而可以无缝集成到全球病理学实验室中。

The collaboration between RTD and PathAI helps advance precision medicine by bringing together AI-interpretation and companion diagnostics, increasing patient access to targeted treatments.

RTD和PathAI之间的合作通过将AI解释和伴随诊断结合在一起，增加了患者获得靶向治疗的机会，从而有助于推进精准医学。

TUCSON, Ariz., Feb. 13, 2024 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has entered into an agreement with PathAI, a global leader in artificial intelligence (AI)-powered technology for pathology.

亚利桑那州图森。，2024年2月13日，罗氏公司（SIX:RO，ROG；OTCQX:RHHBY）今天宣布，它已与人工智能（AI）驱动的病理学技术的全球领导者PathAI达成协议。

Under the terms of this agreement, PathAI will exclusively work with Roche Tissue Diagnostics (RTD) to develop AI-enabled digital pathology algorithms in the companion diagnostics space. RTD will work exclusively with PathAI for a pre-specified term as the sole external algorithm development company for AI-powered companion diagnostics, while retaining the ability to continue to develop its own algorithms for companion diagnostics.

根据该协议的条款，PathAI将专门与Roche Tissue Diagnostics（RTD）合作，在伴随诊断领域开发支持AI的数字病理学算法。RTD将在预先指定的期限内专门与PathAI合作，作为AI支持的伴侣诊断的唯一外部算法开发公司，同时保留继续开发自己的伴侣诊断算法的能力。

PathAI will retain the ability to freely develop algorithms outside of companion diagnostics. .

PathAI将保留在伴随诊断之外自由开发算法的能力。。

'As the market leader in companion diagnostics, we strive to continuously bring new innovations in personalised healthcare,' said Jill German, Head of Roche Tissue Diagnostics. 'This collaboration with PathAI will allow us to accelerate our ability to meet the demand from biopharma companies looking to develop AI-enabled companion diagnostics, and provide them with a powerful end-to-end solution in the pursuit of precision therapeutics.'.

罗氏组织诊断公司（Roche Tissue diagnostics）负责人吉尔·德尔曼（Jill German）说：“作为伴随诊断领域的市场领导者，我们努力不断在个性化医疗保健领域带来新的创新。”与PathAI的合作将使我们能够加速满足生物制药公司的需求，这些公司希望开发支持AI的伴随诊断，并为他们提供强大的端到端解决方案，以追求精确治疗。”。

Algorithms developed under this agreement will be deployed using Roche's Digital Pathology solution.

根据该协议开发的算法将使用罗氏的数字病理解决方案进行部署。

'This collaboration with Roche is a testament to our shared commitment to advancing the field of digital pathology and AI-enabled diagnostics for both drug development and clinical care,' said Dr. Andy Beck, CEO and Co-Founder of PathAI. 'High medical value diagnostic products with seamless integration into the laboratory workflow will accelerate the transition to digital pathology as the standard to aid clinicians in diagnosis and biomarker characterisation.'.

PathAI首席执行官兼联合创始人安迪·贝克（AndyBeck）博士说，与罗氏的合作证明了我们共同致力于推进数字病理学和人工智能诊断领域，以促进药物开发和临床护理无缝集成到实验室工作流程中的高医学价值诊断产品将加速向数字病理学的过渡，作为帮助临床医生进行诊断和生物标志物表征的标准。”。

Under a previous agreement from October of 2021, the companies jointly developed an embedded image analysis workflow for pathologists. This workflow allows PathAI image analysis algorithms to be accessed within Roche's navify® Digital Pathology software platform. PathAI algorithms were the first to be fully integrated into the Roche Open Environment..

根据2021年10月的先前协议，两家公司共同为病理学家开发了嵌入式图像分析工作流程。此工作流程允许在罗氏navify®数字病理软件平台内访问PathAI图像分析算法。PathAI算法是第一个完全集成到罗氏开放环境中的算法。。

About Roche Personalised Healthcare Solutions & Roche Digital PathologyIn collaboration with Roche and other leading pharmaceutical companies, we identify and develop innovative predictive diagnostics to target those patients who are more likely to respond to specific therapies. The global partner of choice for companion diagnostics, we help to advance precision medicine by delivering diagnostic confidence through a broad menu of high medical value solutions that empower physicians to make the right treatment decisions more quickly.

关于罗氏个性化医疗保健解决方案和罗氏数字病理学在与罗氏和其他领先制药公司的合作中，我们确定并开发创新的预测诊断方法，以针对那些更有可能对特定疗法产生反应的患者。作为伴随诊断的全球首选合作伙伴，我们通过广泛的高医学价值解决方案提供诊断信心，帮助医生更快地做出正确的治疗决策，从而帮助推进精准医学。

Our leadership and expertise in digital pathology, including AI-based image analysis algorithms, enables streamlined integration of diagnostic development with the latest in digital pathology solutions to help proliferate the delivery of crucial therapies to patients..

我们在数字病理学领域的领导地位和专业知识，包括基于AI的图像分析算法，能够将诊断开发与最新的数字病理学解决方案进行简化集成，以帮助向患者提供更多关键疗法。。

About Roche Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world's largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world.

关于罗氏于1896年在瑞士巴塞尔成立，作为首批品牌药物工业制造商之一，罗氏已发展成为世界最大的生物技术公司和体外诊断领域的全球领导者。该公司追求卓越的科学发现和开发药物和诊断方法，以改善和挽救世界各地人民的生命。

We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice..

我们是个性化医疗保健的先驱，希望进一步改变医疗保健的交付方式，以产生更大的影响。为了为每个人提供最佳护理，我们与许多利益相关者合作，并将我们在诊断和制药方面的优势与临床实践中的数据见解相结合。。

In recognising our endeavour to pursue a long-term perspective in all we do, Roche has been named one of the most sustainable companies in the pharmaceuticals industry by the Dow Jones Sustainability Indices for the thirteenth consecutive year. This distinction also reflects our efforts to improve access to healthcare together with local partners in every country we work..

由于认识到我们在所有工作中都努力追求长远的观点，罗氏已连续第十三年被道琼斯可持续发展指数评为制药行业最具可持续性的公司之一。这种区别也反映了我们与我们工作的每个国家的当地合作伙伴一起努力改善医疗保健服务。。

Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.

美国的基因泰克是罗氏集团的全资成员。罗氏是日本Chugai Pharmaceutical的大股东。

For more information, please visit www.roche.com.

有关更多信息，请访问www.roche.com。

All trademarks used or mentioned in this release are protected by law.Roche Media Relations

本版本中使用或提及的所有商标均受法律保护。罗氏传媒关系

Jo Lynn Garing, +1 317-363-7286

Jo Lynn Garing，+1 317-363-7286

SOURCE Roche

来源：罗氏